MafB oncoprotein detected by immunohistochemistry as a highly sensitive and specific marker for the prognostic unfavorable t(14;20) (q32;q12) in multiple myeloma patients

Leukemia

Volumn 23, Issue 4, 2009, Pages 801-803

  Stralen, Ev ^a,b   Leguit, R J ^a   Begthel, H ^b   Michaux, L ^c   Buijs, A ^a   Lemmens, H ^c   Scheiff, J M ^d   Doyen, C ^b   Pierre, P ^e   Forget, F ^f   Clevers, H C ^g   Bast, B J E G ^b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b HUBRECHT INSTITUTE   (Netherlands)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d Hôpital Saint Luc   (Belgium)

^e UNIVERSITY HOSPITAL OF MONT GODINNE   (Belgium)

^f Clinic of Saint Joseph   (Belgium)

^g Centre Hospitalier de l'Ardenne   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CD68 ANTIGEN; CYCLIN D2; TRANSCRIPTION FACTOR C MAF; TRANSCRIPTION FACTOR MAFB;

ADULT; ARTICLE; BONE MARROW BIOPSY; CHROMOSOME ANALYSIS; CHROMOSOME DELETION; CHROMOSOME LOSS; CHROMOSOME TRANSLOCATION 14; CHROMOSOME TRANSLOCATION 20; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE LOCUS; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOGLOBULIN HEAVY CHAIN GENE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; MYELOMA CELL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DETERMINATION; PROTEIN FUNCTION; SENSITIVITY AND SPECIFICITY; UPREGULATION; WESTERN BLOTTING;

EID: 64849097804     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2008.284     Document Type: Article

References (11)

1. Chang H, Qi Q, Xu W, Patterson B. c-Maf nuclear oncoprotein is frequently expressed in multiple myeloma. Leukemia 2007; 21: 1572-1574.
2. Boersma-Vreugdenhil GR, Peeters T, Bast BJ, Lokhorst HM. Translocation of the IgH locus is nearly ubiquitous in multiple myeloma as detected by immuno-FISH. Blood 2003; 15: 101-1653.
3. Chng WJ, Glebov O, Bergsagel PL, Kuehl WM. Genetic events in the pathogenesis of multiple myeloma. Best Pract Res Clin Haematol 2007; 20: 571-596.
4. Yang Y, Cvekl A. Large Maf transcription factors: Cousins of AP-1 proteins and important regulators of cellular differentiation. Einstein J Biol Med 2007; 23: 2-11.
5. Boersma-Vreugdenhil GR, Kuipers J, Van Stralen E, Peeters T, Michaux L, Hagemeijer A et al. The recurrent translocation t (14;20)(q32;q12) in multiple myeloma results in aberrant expression of MAFB: A molecular and genetic analysis of the chromosomal breakpoint. Br J Haematol 2004; 126: 355-363.
6. van Noort M, Meeldijk J, van der Zee R, Destree O, Clevers H. Wnt signaling controls the phosphorylation status of beta-catenin. J Biol Chem 2002; 277: 17901-17905.
7. Sieweke MH, Tekotte H, Frampton J, Graf T. MafB is an interaction partner and repressor of Ets-1 that inhibits erythroid differentiation. Cell 1996; 85: 49-60.
8. Chang H, Stewart AK, Qi XY, Li ZH, Yi QL, Trudel S. Immunohistochemistry accurately predicts FGFR3 aberrant expression and t (4;14) in multiple myeloma. Blood 2005; 106: 353-355.
9. Hurt EM, Wiestner A, Rosenwald A, Shaffer AL, Campo E, Grogan T et al Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma. Cancer Cell 2004; 5: 191-199.
10. Rasmussen T, Knudsen LM, Dahl IM, Johnsen HE. C-MAF oncogene dysregulation in multiple myeloma: Frequency and biological relevance. Leuk lymphoma 2003; 44: 1761-1766.
11. Trudel S, Stewart AK, Rom E, Wei E, Li ZH, Kotzer S et al. The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t (4;14) multiple myeloma cells. Blood 2006; 107: 4039-4046.